Starling Oncology
STLN
53 hedge funds and large institutions have $215M invested in Starling Oncology in 2021 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 8 closing their positions.
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
6% more funds holding
Funds holding: 50 → 53 (+3)
18% less capital invested
Capital invested by funds: $261M → $215M (-$45.9M)
19.86% less ownership
Funds ownership: 113.76% → 93.89% (-20%)
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
+$7.21M |
| 2 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
+$6.28M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$4.65M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$2.37M |
| 5 |
PMAM
Picton Mahoney Asset Management
Toronto,
Ontario, Canada
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$55M |
| 2 |
ECM
Element Capital Management
New York
|
-$5.97M |
| 3 |
SRCM
Sage Rock Capital Management
New York
|
-$4.71M |
| 4 |
KC
Kepos Capital
New York
|
-$2.96M |
| 5 |
GCL
Glazer Capital LLC
New York
|
-$1.09M |
STLN Hedge Fund Activity: Q2 2021 in Review
53 of the 5,768 institutional investors tracked by Wall St. Rank reported a position in Starling Oncology (STLN) for Q2 2021, worth a combined $215M — down 18% from $261M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new STLN positions and 8 closed out — a net gain of 4 holders — while 5 added to existing stakes and 14 trimmed.
The largest buyer was 683 Capital Management, opening a new position worth an estimated $7.21M. The largest seller was Deerfield Management, cutting an estimated $55M.
- 53 institutional investors held Starling Oncology (STLN) as of Q2 2021, up from 50 in Q1 2021.
- Funds reported $215M of Starling Oncology stock for Q2 2021, down 18% quarter-over-quarter.
- 12 funds opened new Starling Oncology positions in Q2 2021 and 8 closed out, a net change of +4 holders.
- The largest Starling Oncology buyer in Q2 2021 was 683 Capital Management, an estimated $7.21M added.
- The largest Starling Oncology seller in Q2 2021 was Deerfield Management, an estimated $55M sold.
Based on aggregated 13F filings for Q2 2021.